University of California San Francisco

Jennifer Rosenbluth, MD, PhD

Jennifer Rosenbluth, MD, PhD
Jennifer Rosenbluth, MD, PhD

Associate Professor, Medicine

Sulochana Pradhan, MD Distinguished Professor in Breast Cancer

Address

10 Koret Way, #231
San Francisco, CA 94117
United States

Email: [email protected]

Education

Institution Degree Dept or School End Date
Dana-Farber Cancer Institute Medical Oncology
Massachusetts General Hospital Internal Medicine
Princeton University AB
Vanderbilt University School of Medicine MD
Vanderbilt University School of Medicine PhD

Awards & Honors

Award Conferred By Date
Investigator Award Chan Zuckerberg Biohub 2022
Young Investigator Grant Breast Cancer Alliance 2021
Clinical Scientist Development Award Doris Duke Charitable Foundation 2021
Fellowship Award Terri Brodeur Breast Cancer Foundation 2021
Sulochana Pradhan, MD Endowed Professorship in Breast Cancer UCSF 2021
Sidney Farber Scholar Dana-Farber Cancer Institute 2020/2021
Eleanor and Miles Shore Award Dana-Farber Cancer Institute 2019/2020
Career Catalyst Research Grant Susan G. Komen Foundation 2019
Postdoctoral Fellowship American Cancer Society 2017/2019
Young Investigator Award American Society of Clinical Oncology 2017/2018
Leadership Council Fellow Dana-Farber Cancer Institute 2014
Dean's Award for Research Vanderbilt University 2011
John G. Coniglio Prize for Excellence in Biochemistry Vanderbilt University 2011

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 38
  1. A Shape Analysis Algorithm Quantifies Spatial Morphology and Context of 2D to 3D Cell Culture for Correlating Novel Phenotypes with Treatment Resistance.
    Nguyen DH, Bruck M, Rosenbluth JM| | PubMed
  2. Stress-relaxing granular bioprinting materials enable complex and uniform organoid self-organization.
    Graham AJ, Khoo MWL, Srivastava V, Viragova S, Kim H, Parekh K, Hennick KM, Bird M, Goldhammer N, Yu JZ, Hu G, Brinkley NT, Pardo L, Amaya JS, Morley CD, Chadha N, Lebel P, Kumar S, Rosenbluth JM, Nowakowski TJ, Chaudhuri O, Klein O, Gómez-Sjöberg R, Gartner ZJ| | PubMed
  3. Hormone signaling and immune programs define differential endocrine responsiveness in high-risk breast tissue
    Nadine Goldhammer, Marin Bont, Shruti Warhadpande, Michael Choi, Jose Cedano, Heather Greenwood, Julia Ye, Christopher Schwartz, Michael Alvarado, Cheryl Ewing, Karen Goodwin, Rita Mukhtar, Jasmine Wong, Shoko Abe, Julia Chandler, Jordan Jackson, Olufunmilayo Olopade, Michael Campbell, Allison Lam, Chaelee Park, Anna Vertido, Laura van 't Veer, Nola Hylton, Laura Esserman, Jennifer Rosenbluth| | UCSF Research Profile
  4. Hormone signaling and immune programs define differential endocrine responsiveness in high-risk breast tissue.
    Goldhammer N, Bont M, Warhadpande S, Choi M, Cedano J, Greenwood H, Ye J, Schwartz CJ, Alvarado M, Ewing C, Goodwin K, Mukhtar RA, Wong J, Abe SE, Chandler J, Jackson J, Olopade OI, Campbell MJ, Lam A, Park C, Vertido A, van 't Veer LJ, Hylton N, Esserman LJ, Rosenbluth JM| | PubMed
  5. METTL3-dependent m6A RNA methylation suppresses aberrant mammary epithelial differentiation and neoplastic transformation.
    Li Y, Qiu X, Sandusky Z, Tagliaferri K, Li R, Yang X, Zhang T, Liu S, Yan P, Lu F, Jones M, Xiao T, Li W, Goldman S, Cui J, Polyak K, Liu XS, Long HW, Gregory RI, Adelman K, Rosenbluth JM, Brown M| | PubMed
  6. EpiBlot: Joint Mapping of Chromatin Accessibility and Targeted Proteomics in HER2-expressing Breast Cancer Systems.
    Khartchenko AF, Lam T, Goldhammer N, Bont M, Warhadpande S, Rosenbluth JM, Herr AE| | PubMed
  7. FNA biopsy of breast specimens effectively harvests cells for patient-derived organoids modeling ductal carcinoma in situ.
    Ye J, Goldhammer N, Vohra P, Warhadpande S, de Castro GC, Rodas CKM, Moasser MM, Ramalingam K, Abe SE, Alvarado M, Ewing C, Goodwin KM, Mukhtar RA, Wong JM, Esserman LJ, Balassanian R, Rosenbluth JM| | PubMed
  8. Stress relaxing granular bioprinting materials enable complex and uniform organoid self-organization.
    Graham AJ, Khoo MWL, Srivastava V, Viragova S, Kim H, Parekh K, Hennick KM, Bird M, Goldhammer N, Yu JZ, Hu G, Brinkley NT, Pardo L, Amaya JS, Morley CD, Chadha N, Lebel P, Kumar S, Rosenbluth JM, Nowakowski TJ, Chaudhuri O, Klein O, Gómez-Sjöberg R, Gartner ZJ| | PubMed
  9. Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapies.
    Bui TBV, Wolf DM, Bruck MC, Moore K, Lien J, Choi SDW, Warhadpande S, Parizadeh A, Dillon D, Overmoyer B, Lynce F, I-SPY 2 Investigators, Nijman IJ, Burgering BMT, Harris IS, Esserman LJ, Veer LJV', Rosenbluth JM| | PubMed
  10. Autophagy-targeted NBR1-p62/SQSTM1 complexes promote breast cancer metastasis by sequestering ITCH.
    Mondal G, Gonzalez H, Marsh T, Leidal AM, Vlahakis A, Phadatare PR, Bustamante Eguiguren S, Bruck M, Naik A, Magbanua MJM, Huppert LA, Wiita AP, Roose JP, Rosenbluth JM, Debnath J| | PubMed
  11. AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization.
    Phi LTH, Cheng Y, Funakoshi Y, Bertucci F, Finetti P, Van Laere SJ, Zou F, Long JP, Ogata S, Krishnamurthy S, Reuben JM, Foulks JM, Warner SL, Rosenbluth JM, Sood AK, Tripathy D, Ueno NT, Wang X| | PubMed
  12. Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.
    Ramalingam K, Woody R, Glencer A, Schwartz CJ, Mori H, Wong J, Hirst G, Rosenbluth J, Onishi N, Gibbs J, Hylton N, Borowsky AD, Campbell M, Esserman LJ| | PubMed
  13. Implantation of engineered adipocytes suppresses tumor progression in cancer models.
    Nguyen HP, An K, Ito Y, Kharbikar BN, Sheng R, Paredes B, Murray E, Pham K, Bruck M, Zhou X, Biellak C, Ushiki A, Nobuhara M, Fong SL, Bernards DA, Lynce F, Dillon DA, Magbanua MJM, Huppert LA, Hammerlindl H, Klein JA, Valdiviez L, Fiehn O, Esserman L, Desai TA, Yee SW, Rosenbluth JM, Ahituv N| | PubMed
  14. T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation.
    Cho NW, Guldberg SM, Nabet BY, Yu JZ, Kim EJ, Hiam-Galvez KJ, Yee JL, DeBarge R, Tenvooren I, Ashitey NA, Lynce F, Dillon DA, Rosenbluth JM, Spitzer MH| | PubMed
  15. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
    Greenwood HI, Maldonado Rodas CK, Freimanis RI, Glencer AC, Miller PN, Mukhtar RA, Brabham C, Yau C, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky A, Hylton N, Esserman LJ, Basu A| | PubMed
  16. Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer.
    Garrido-Castro AC, Regan MM, Niman SM, Nakhlis F, Remolano C, Rosenbluth JM, Block C, Warren LE, Bellon JR, Yeh E, Harrison BT, Troll E, Lin NU, Tolaney SM, Overmoyer B, Lynce F| | PubMed
  17. Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression.
    Nguyen HP, Sheng R, Murray E, Ito Y, Bruck M, Biellak C, An K, Lynce F, Dillon DA, Magbanua MJM, Huppert LA, Hammerlindl H, Esserman L, Rosenbluth JM, Ahituv N| | PubMed
  18. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
    Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ| | PubMed
  19. A human breast atlas integrating single-cell proteomics and transcriptomics.
    Gray GK, Li CM, Rosenbluth JM, Selfors LM, Girnius N, Lin JR, Schackmann RCJ, Goh WL, Moore K, Shapiro HK, Mei S, D'Andrea K, Nathanson KL, Sorger PK, Santagata S, Regev A, Garber JE, Dillon DA, Brugge JS| | PubMed
  20. Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer.
    Hirko KA, Regan MM, Remolano MC, Schlossman J, Harrison B, Yeh E, Jacene H, Nakhlis F, Block C, Rosenbluth JM, Garrido-Castro AC, Overmoyer BA| | PubMed
  21. Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids.
    Dekkers JF, van Vliet EJ, Sachs N, Rosenbluth JM, Kopper O, Rebel HG, Wehrens EJ, Piani C, Visvader JE, Verissimo CS, Boj SF, Brugge JS, Clevers H, Rios AC| | PubMed
  22. Aging-Associated Alterations in Mammary Epithelia and Stroma Revealed by Single-Cell RNA Sequencing.
    Li CM, Shapiro H, Tsiobikas C, Selfors LM, Chen H, Rosenbluth J, Moore K, Gupta KP, Gray GK, Oren Y, Steinbaugh MJ, Guerriero JL, Pinello L, Regev A, Brugge JS| | PubMed
  23. Characteristics associated with inflammatory breast cancer (IBC): An epidemiologic study from a dedicated IBC program.
    White RE, Warren L, Nakhlis F, Rosenbluth J, Bellon J, Block C, Overmoyer B| | PubMed
  24. Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning.
    Jacene HA, DiPiro PJ, Bellon J, Hu J, Cheng SC, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth JM, Yeh E, Overmoyer B| | PubMed
  25. Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages.
    Rosenbluth JM, Schackmann RCJ, Gray GK, Selfors LM, Li CM, Boedicker M, Kuiken HJ, Richardson A, Brock J, Garber J, Dillon D, Sachs N, Clevers H, Brugge JS| | PubMed
  26. A large peptidome dataset improves HLA class I epitope prediction across most of the human population.
    Sarkizova S, Klaeger S, Le PM, Li LW, Oliveira G, Keshishian H, Hartigan CR, Zhang W, Braun DA, Ligon KL, Bachireddy P, Zervantonakis IK, Rosenbluth JM, Ouspenskaia T, Law T, Justesen S, Stevens J, Lane WJ, Eisenhaure T, Lan Zhang G, Clauser KR, Hacohen N, Carr SA, Wu CJ, Keskin DB| | PubMed
  27. Inflammatory Breast Cancer: a Separate Entity.
    Rosenbluth JM, Overmoyer BA| | PubMed
  28. Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion.
    Harris IS, Endress JE, Coloff JL, Selfors LM, McBrayer SK, Rosenbluth JM, Takahashi N, Dhakal S, Koduri V, Oser MG, Schauer NJ, Doherty LM, Hong AL, Kang YP, Younger ST, Doench JG, Hahn WC, Buhrlage SJ, DeNicola GM, Kaelin WG, Brugge JS| | PubMed
  29. Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade.
    Jacene HA, Youn T, DiPiro PJ, Hu J, Cheng SC, Franchetti Y, Shah H, Bellon JR, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth J, Yeh E, Overmoyer B, Dana-Farber Cancer Institute Inflammatory Breast Cancer Program| | PubMed
  30. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene
    Jovanovic B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA| | PubMed
  31. p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network.
    Marshall CB, Mays DJ, Beeler JS, Rosenbluth JM, Boyd KL, Santos Guasch GL, Shaver TM, Tang LJ, Liu Q, Shyr Y, Venters BJ, Magnuson MA, Pietenpol JA| | PubMed
  32. Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis.
    Rosenbluth JM, Mays DJ, Jiang A, Shyr Y, Pietenpol JA| | PubMed
  33. ISG20L1 is a p53 family target gene that modulates genotoxic stress-induced autophagy.
    Eby KG, Rosenbluth JM, Mays DJ, Marshall CB, Barton CE, Sinha S, Johnson KN, Tang L, Pietenpol JA| | PubMed
  34. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.
    Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM, Means-Powell JA, Johnson KN, Tsai CJ, Ayers GD, Sanders ME, Schneider RJ, Formenti SC, Caprioli RM, Pietenpol JA| | PubMed
  35. Evaluation of p63 and p73 antibodies for cross-reactivity.
    Rosenbluth JM, Johnson K, Tang L, Triplett T, Pietenpol JA| | PubMed
  36. mTOR regulates autophagy-associated genes downstream of p73.
    Rosenbluth JM, Pietenpol JA| | PubMed
  37. The jury is in: p73 is a tumor suppressor after all.
    Rosenbluth JM, Pietenpol JA| | PubMed
  38. A gene signature-based approach identifies mTOR as a regulator of p73.
    Rosenbluth JM, Mays DJ, Pino MF, Tang LJ, Pietenpol JA| | PubMed